![Jason Myers](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason Myers
Directeur/Bestuurslid bij
Venn Biosciences Corp.
Profiel
Jason W.
Myers was the founder of ArcherDX LLC, founded in 2013, where the titles held included President, Chief Executive Officer & Director from 2015 to 2020.
Dr. Myers currently serves as Director at Venn Biosciences Corp.
since 2022.
Former positions include Director at Invitae Corp.
from 2020 to 2021; Independent Director at IsoPlexis Corp.
from 2021 to 2023; President & Director at Singular Genomics Systems, Inc.; Chief Executive & Financial Officer, Director at GenapSys, Inc. from 2021 to 2022; Chief Scientific Officer at Universal Display Corp.
from 2013 to 2015; and Chief Scientific Officer at QIAGEN Beverly LLC.
Education includes undergraduate studies at Colorado State University and a doctorate from Stanford University School of Medicine.
Actieve functies van Jason Myers
| Bedrijven | Functie | Begin |
|---|---|---|
Venn Biosciences Corp.
 Venn Biosciences Corp. BiotechnologyHealth Technology Operates as a life sciences company unlocking the value of glycoproteomic for the development of transformational healthcare solutions by using AI | Directeur/Bestuurslid | 04-10-2022 |
Eerdere bekende functies van Jason Myers
| Bedrijven | Functie | Einde |
|---|---|---|
| ISOPLEXIS CORPORATION | Directeur/Bestuurslid | 21-03-2023 |
GenapSys, Inc.
 GenapSys, Inc. Miscellaneous Commercial ServicesCommercial Services Develops genomic sequencing ecosystem designed to empower academic and clinical research applications | Algemeen Directeur | 01-09-2022 |
| INVITAE CORPORATION | Directeur/Bestuurslid | 05-07-2021 |
ArcherDX LLC
 ArcherDX LLC Packaged SoftwareTechnology Services Develops software solutions for investigating cancer treatment | Oprichter | 02-10-2020 |
| UNIVERSAL DISPLAY CORPORATION | Hoofd Techniek/Wetenschap/O&O | 01-01-2015 |
Opleiding van Jason Myers
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
61
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Universal Display Corp.
 Universal Display Corp. Electronic Production EquipmentElectronic Technology Engages in research, development and commercialization of organic light emitting diode (OLED), technologies and materials | Electronic Technology |
QIAGEN Beverly LLC
 QIAGEN Beverly LLC BiotechnologyHealth Technology Manufactures enzymes and biological reagents | Health Technology |
Invitae Corp.
 Invitae Corp. Medical/Nursing ServicesHealth Services Provides genetic testing services for patients | Health Services |
GenapSys, Inc.
GenapSys, Inc. Miscellaneous Commercial ServicesCommercial Services Develops genomic sequencing ecosystem designed to empower academic and clinical research applications | Commercial Services |
IsoPlexis Corp.
 IsoPlexis Corp. Medical SpecialtiesHealth Technology Develops single cell multiplexing immunoassay systems | Health Technology |
Colorado State University
 Colorado State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ArcherDX LLC
ArcherDX LLC Packaged SoftwareTechnology Services Develops software solutions for investigating cancer treatment | Technology Services |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Singular Genomics Systems, Inc.
 Singular Genomics Systems, Inc. Miscellaneous Commercial ServicesCommercial Services Develops scalable spatial multiomics technology for precision diagnostics and personalized medicine | Commercial Services |
Venn Biosciences Corp.
Venn Biosciences Corp. BiotechnologyHealth Technology Operates as a life sciences company unlocking the value of glycoproteomic for the development of transformational healthcare solutions by using AI | Health Technology |
